Drug intelligence / Profile preview

ORT

Development stage: Preclinical
Lead developer: The First Affiliated Hospital
Administration: Oral, Nasogastric, Gastrostomy

Overview

ORT is a drug currently under investigation for its potential therapeutic effects in the treatment of primary central nervous system lymphoma. It is being studied in clinical trials, sometimes in combination with high-dose methotrexate (MTX). Due to the non-specific nature of the abbreviation "ORT", detailed information regarding its specific mechanism of action, molecular structure, or developer beyond the clinical trial sponsor is not readily available in general public databases.

Beyond the preview

Go deeper on ORT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ORT.

Explore the full profile